ResMed/$RMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ResMed
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Ticker
$RMD
Sector
Primary listing
NYSE
Employees
10,600
Headquarters
Website
ResMed Metrics
BasicAdvanced
$40B
28.52
$9.51
0.77
$2.12
0.78%
Price and volume
Market cap
$40B
Beta
0.77
52-week high
$293.81
52-week low
$199.92
Average daily volume
1M
Dividend rate
$2.12
Financial strength
Current ratio
3.44
Quick ratio
2.109
Long term debt to equity
13.596
Total debt to equity
14.273
Dividend payout ratio (TTM)
22.19%
Interest coverage (TTM)
2,884.43%
Profitability
EBITDA (TTM)
1,860.397
Gross margin (TTM)
59.99%
Net profit margin (TTM)
27.22%
Operating margin (TTM)
32.79%
Effective tax rate (TTM)
16.50%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
14.02%
Return on equity (TTM)
25.86%
Valuation
Price to earnings (TTM)
28.516
Price to revenue (TTM)
7.731
Price to book
6.65
Price to tangible book (TTM)
16.17
Price to free cash flow (TTM)
24.1
Free cash flow yield (TTM)
4.15%
Free cash flow per share (TTM)
11.253
Dividend yield (TTM)
0.78%
Forward dividend yield
0.78%
Growth
Revenue change (TTM)
9.84%
Earnings per share change (TTM)
37.43%
3-year revenue growth (CAGR)
12.88%
10-year revenue growth (CAGR)
11.85%
3-year earnings per share growth (CAGR)
21.52%
10-year earnings per share growth (CAGR)
14.43%
3-year dividend per share growth (CAGR)
8.06%
10-year dividend per share growth (CAGR)
6.59%
What the Analysts think about ResMed
Analyst ratings (Buy, Hold, Sell) for ResMed stock.
Bulls say / Bears say
ResMed delivered 10% year-over-year revenue growth to $1.348 billion and 23% non-GAAP EPS growth in Q4 FY 2025, driven by 230 bps of gross margin expansion (Globe Newswire)
The May 2025 acquisition of VirtuOx enhances ResMed’s at-home diagnostic capabilities, streamlining patient access to sleep and respiratory testing within its digital care ecosystem (Globe Newswire)
Strong capital allocation in Q4 FY 2025 included a 13% dividend increase to $0.60/share and $100 million in share repurchases, supported by $539 million of operating cash flow (Globe Newswire)
Extended valuation at 23.7x expected earnings, near a three-year high, limits the margin of safety if growth decelerates (Barron's)
Ongoing regulatory uncertainties and sector underperformance in U.S. healthcare have weighed on stocks like ResMed, potentially dampening investor sentiment (Reuters)
The VirtuOx acquisition brings only an approximate $45 million annual revenue run rate—under 1% of ResMed’s consolidated revenue—indicating a limited near-term financial impact (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
ResMed Financial Performance
Revenues and expenses
ResMed Earnings Performance
Company profitability
ResMed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept18
ResMed
DividendPayment
$0.60Per share
FAQs
What’s the current market cap for ResMed stock?
ResMed (RMD) has a market cap of $40B as of September 16, 2025.
What is the P/E ratio for ResMed stock?
The price to earnings (P/E) ratio for ResMed (RMD) stock is 28.52 as of September 16, 2025.
Does ResMed stock pay dividends?
Yes, the ResMed (RMD) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is $2.12 and the yield is 0.78%. ResMed has a payout ratio of 22.19% on a trailing twelve-month basis.
When is the next ResMed dividend payment date?
The next ResMed (RMD) dividend payment is scheduled for September 18, 2025.
What is the beta indicator for ResMed?
ResMed (RMD) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.